Washington Court of Appeals Challenges Insurance Bans on Weight Loss Drugs
A recent legal development in Washington state could fundamentally change how health insurance companies handle coverage for obesity medications. In a decision published May 4, the Washington Court of Appeals revived a legal challenge against health insurers that use blanket refusals to deny coverage for weight loss medications, such as Ozempic and Wegovy.
The court ruled that insurance plans prohibiting certain types of obesity treatment could potentially violate state antidiscrimination laws. This decision opens the door to a legal battle that may eventually strike down blanket bans on weight loss drug coverage across the state, potentially making these high-cost medications more accessible to the general public.
The Legal Fight Over GLP-1 Coverage
The controversy centers on a class of medications known as GLP-1 drugs. While these medications are approved by the Food and Drug Administration (FDA) for the treatment of obesity and other conditions, they remain prohibitively expensive for many patients. Many health insurance plans explicitly refuse to cover these drugs if they are prescribed solely for weight loss.
Because of these exclusions, patients often face costs of hundreds of dollars per month out of pocket. This financial barrier frequently forces patients to either go without necessary treatment or seek out compounded versions of the medications.
A Nurse’s Battle for Access
The current legal challenge stems from a 2023 lawsuit filed by Jeannette Simonton, a nurse and resident of Ellensburg. Simonton’s physician prescribed a GLP-1 drug to treat her obesity, specifically to help her lose 40 pounds so she could qualify for knee surgery.
Simonton obtained insurance through the Washington State Health Care Authority, which manages plans for state employees. When the authority denied coverage for the medication, Simonton filed suit. Speaking on her motivation for the legal action, Simonton stated, “The lawsuit I filed because as a nurse I was very upset at people not having access to this medication.”
Why Coverage is Often Denied
The gap between FDA approval and insurance coverage is a recurring point of friction in obesity care. Although medical authorities recognize obesity as a chronic disease requiring treatment, insurers often categorize weight loss medications as “lifestyle” drugs rather than essential medical treatments. By implementing blanket bans, insurers avoid the high costs associated with these blockbuster medications, regardless of the individual patient’s medical necessity—such as Simonton’s need for surgery.
What This Means for the Future of Obesity Treatment
While the May 4 ruling does not automatically guarantee coverage for all patients, it establishes a critical legal precedent. By suggesting that blanket bans may violate antidiscrimination laws, the court has shifted the burden onto insurers to justify these exclusions.
If the legal battle concludes in favor of the plaintiffs, it could force insurers in Washington to evaluate weight loss medications on a case-by-case basis or remove blanket prohibitions entirely. Such a shift would significantly increase the affordability and accessibility of GLP-1 drugs for those struggling with obesity.
Key Takeaways: Washington State Insurance Ruling
- The Ruling: The Washington Court of Appeals found that blanket bans on obesity treatments could potentially violate state antidiscrimination laws.
- The Medications: The case specifically involves GLP-1 drugs like Ozempic and Wegovy.
- The Catalyst: A lawsuit filed by nurse Jeannette Simonton after the Washington State Health Care Authority denied her coverage for medication needed prior to knee surgery.
- The Potential Impact: A final victory for the plaintiffs could eliminate blanket coverage bans, making expensive weight loss medications widely accessible in Washington.